Novo Nordisk Gains UK MASH Approval but Overbought Charts and Cyber Probe Temper Euphoria
Published on 07/05/2026 at 10:54 | Redaktion boerse-global.de
Novo Nordisk picked up a new regulatory win in Britain on 3 July 2026, when the MHRA granted conditional approval for Wegovy (semaglutide) to treat MASH — a fatty liver disease with moderate to advanced fibrosis. The decision opens a fresh indication beyond weight loss and cardiovascular risk reduction, though it comes with strings attached. The Danish drugmaker must submit additional data from an ongoing study before full market authorisation, and the National Institute for Health and Care Excellence is still weighing whether the treatment offers value for money within the NHS. That review will ultimately determine how quickly the approval translates into prescriptions and revenue.
The good news from London arrived as Novo Nordisk’s stock sits in technically overbought territory. The 14-day relative strength index hit 71.2 on Friday, a level that historically signals a pause or pullback. The shares closed at €43.50, up 19.52% over the past month but still 25.92% lower than a year ago and 28.92% below the 52-week high of €61.20 set last July. Trading more than 12% above the 50-day moving average of €38.72 and roughly 6% above the 200-day average of €40.80, the rally leaves little cushion for a reversal.
Compounding the technical strain is an unresolved cyberattack first disclosed in June. Unauthorised access to a limited portion of internal systems was confirmed, and unnamed extortionists claim to have stolen a far larger trove — including proprietary data on marketed and experimental drugs such as Amycretin and CagriSema, along with clinical trial results. Novo Nordisk has neither verified the scope of those claims nor disclosed any ransom demand, but it has brought in external cybersecurity experts and informed affected parties. The investigation remains active, with authorities involved.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analyst sentiment reflects the crosscurrents. DNB Carnegie, a historically bullish voice, trimmed its price target on the stock from 430 to 420 Danish kroner while keeping a buy rating — a nod to lower near-term estimates but intact long-term conviction. That move fits a wider pattern: Nordic and German analysts tend to cluster around “buy” ratings with targets of 300 to 440 DKK, while their Wall Street counterparts lean toward “hold” with lower price objectives. The geographic divide underscores disagreement over how Novo Nordisk will hold its ground against Eli Lilly in the fast-expanding GLP-1 market, particularly in the United States.
Optimists point to tangible pipeline and regulatory momentum beyond the UK nod. The European Medicines Agency has already issued a positive recommendation for the oral Wegovy pill, and US sales of that formulation are surging: roughly 1.3 million prescriptions were written in the first quarter of 2026, with cumulative scripts exceeding 2 million since launch — the strongest GLP-1 product debut in American history. Phase 3 data from the REIMAGINE study of CagriSema, the company’s next-generation combination therapy for obesity and diabetes, were presented at the ADA Scientific Sessions 2026, demonstrating effects on glycaemic control and weight loss across different background diabetes treatments. The stock has already rebounded 43.8% from its March trough of €30.25.
Yet the bears have ammunition of their own. An RSI north of 70 is historically followed by a consolidation phase, and the price sits more than 12% above its 50-day average — a stretched setup by any technical measure. Meanwhile, in head-to-head trial comparisons, CagriSema produced a 23.0% weight loss after 84 weeks, trailed by Eli Lilly’s tirzepatide, which delivered higher numbers. If the cyber investigation uncovers material leakage of pipeline secrets or competitive data, the downside risk would compound a naturally overextended chart. The first line of support would then be the 50-day moving average at €38.72.
The weeks ahead will be shaped by several concrete catalysts: further updates on the IT security probe, the second-quarter 2026 earnings release expected later in the summer, and the NICE appraisal of Wegovy for MASH. Should the cyber case close without evidence of material operational or competitive damage, and should CagriSema’s regulatory path continue to advance, the overbought condition may resolve as a mere pause rather than a trend reversal. Conversely, a damaging disclosure or a Lilly-driven loss of momentum could deepen the consolidation, testing the recent rebound’s durability.
Ad
Novo Nordisk Stock: New Analysis - 5 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
